← Russell 3000 cross-section

WGS GeneDx Holdings Corp.

Trailing twelve months to 2026-06-30 · as filed 2026-08-03, not restated
Healthcare

Scale

Market cap
$2.7bn
Revenue TTM
$454m
Net income TTM
$-106m
Free cash flow
$-76m
Composite score
40.6
Sector rank
#1461

Valuation

P / E
EV / EBITDA
EV / sales
5.9
FCF yield
-2.79%
Earnings yield vs 10-yr
-8.65pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-23.4%
EBITDA margin
-17.9%
ROE
-43.5%
ROIC
-44.3%
Revenue growth
25.4%

Insider activity, last 90 days

Net open-market
$9.96m
Buyers
1
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

No single payor or individual client accounted for more than 10% of revenue or receivables for the current period. The measurement period for the First Milestone Payment was completed on December 31, 2025, and the Company determined the amount of the liability based on the gross revenue and gross margin achieved by Fabric Genomics for the year ended December 31, 2025. We generally expect our selling, general and administrative expenses to continue to increase in absolute dollars as we expand our commercial sales, marketing and counseling teams, increase marketing activities, grow our administrative infrastructure, and incur costs associated with operating as a public company, including legal …GeneDx Holdings Corp., 10-Q, period ended 2026-06-30, filed 2026-08-03

Read the full passage →